


**BEST AVAILABLE COPY**

08-13-02



AUG 12 2007

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

## **SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Docket Number:  
**1662/54902**

Application Number  
**10/045,510**

Filing Date  
**October 19, 2001**

**Examiner  
not yet assigned**

Art Unit  
1621

**Invention Title**

# **CRYSTALLINE VENLAFAXINE BASE AND NOVEL POLYMORPHS OF VENLAFAXINE HYDROCHLORIDE, PROCESSES FOR PREPARING THEREOF**

## Inventors

DOLITZKY et al.

**Address to:**

Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being transmitted by the United States Postal Service as first class mail at the above address to: Commissioner for Patents, Washington, D.C. 20591, on

Date 8/12/03

**Signature**

**KENYON & KENYON**

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the reference listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: 8/12/02

By:

Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)

# BEST AVAILABLE COPY

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>ATTY. DOCKET NO.</b> <b>01662/54902</b>	<b>SERIAL NO.</b> <b>10/045,510</b>
	<b>APPLICANT</b> <b>DOLITZKY et al.</b>	
	<b>FILING DATE</b> <b>October 19, 2001</b>	<b>GROUP</b> <b>1621</b>

## U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUB-CLASS	FILING DATE*
	4,611,078	Sept. 9, 1986	Husbands et al.			

\* - if pertinent

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/32555	June 8, 2000	PCT			N/A	
	WO 02/36542	May 10, 2002	PCT			N/A	
	WO 02/46140	June 13, 2002	PCT			N/A	

## OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	J.P. Yardley, et al., 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity, Journal of Medicinal Chemistry, 1990, 33, pp. 2899-2905

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	